Clinical Infectious Diseases

The world's leading journal on infectious diseases. Clinical ID, public health, microbiology, and everything in-between. Official publication of @IDSAinfo

[Clinical Infectious Diseases @CIDJournal]

Virological Response Versus Clinical Benefit in HAM/TSP

✅ Just Accepted
#IDTwitter

🔗 https://t.co/fMuB2q0jda

[Clinical Infectious Diseases @CIDJournal]

The role of dolutegravir on therapy of HTLV-1 infection

✅ Just Accepted
#IDTwitter

🔗 https://t.co/q0KtwnDDnX

[Clinical Infectious Diseases @CIDJournal]

Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial

✅ Just Accepted
✍️ @Auruminstitute
🔗 https://t.co/UyVIuVyCkW

[Clinical Infectious Diseases @CIDJournal]

A randomized clinical trial to compare moxiFloxAcin veRsus aziTHromycin for the trEatment of MycoplaSma geniTalium: the FARTHEST Study

✅ Just Accepted
🔗 https://t.co/HeUhyx4Gel

[Clinical Infectious Diseases @CIDJournal]

Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial

✅ Just Accepted
🔗 https://t.co/l6DuynBLyH

[Clinical Infectious Diseases @CIDJournal]

The latest CID supplement issue highlights new innovations in the infectious disease community.

↪️ https://t.co/lAiCUBLi0V

[Clinical Infectious Diseases @CIDJournal]

Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis

✅ Just Accepted
🔗 https://t.co/cwTg9H29Cb

[Clinical Infectious Diseases @CIDJournal]

The Best of Both Worlds: How Combining a Large Language Model and a Rule-Based Algorithm Makes CAUTI Surveillance More Efficient

✅ Just Accepted
https://t.co/IDcfibFbk4

[Clinical Infectious Diseases @CIDJournal]

AI Patient Safety Tools That Augment Human Effort

✅ Just Accepted
✍️ @dr_dmorgan
#IDTwitter

🔗 https://t.co/h94qbMpkl1

[Clinical Infectious Diseases @CIDJournal]

Health-Related Quality of Life in Well-treated People With HIV and Comparators Over an 8-year Period: A Longitudinal Analysis From the Prospective AGEhIV Cohort Study

✅ Just Accepted
https://t.co/ye5DTG0nKY

[Clinical Infectious Diseases @CIDJournal]

Fatal Case of Human B Virus Infection Manifesting With Hemorrhagic Encephalitis and Chorioretinitis

✅ Just Accepted
🔗 https://t.co/GlscC6sAoY

[Clinical Infectious Diseases @CIDJournal]

Risk of Measles Outbreak in Texas School Districts: A Modeling Study

✅ Just Accepted
#IDTwitter
https://t.co/ACZPocpLpI

[Clinical Infectious Diseases @CIDJournal]

The latest CID supplement issue highlights new innovations in the infectious disease community.

↪️ https://t.co/lAiCUBLi0V

[Clinical Infectious Diseases @CIDJournal]

Is One All We Really Need? Reply to Lorenz et al Regarding Shorter Duration of Benzathine Penicillin G Therapy for Late or Unknown Duration Syphilis

✅ Just Accepted
🔗 https://t.co/uc4Smdpqdq

[Clinical Infectious Diseases @CIDJournal]

Serological Response After Shorter Durations of Therapy for Syphilis of Late Latent or Unknown Duration: What Does It Mean?

✅ Just Accepted
🔗 https://t.co/Po3U6dz955

[Clinical Infectious Diseases @CIDJournal]

Efficacy Is Not Enough: Delivering Tuberculosis Preventive Therapy in the Real World

✅ Just Accepted
🔗 https://t.co/tqWOUPCzj6

[Clinical Infectious Diseases @CIDJournal]

Clarification of PSA methods and corrected CEAC for universal HDV testing among adults with chronic HBV

✅ Just Accepted
🔗 https://t.co/wRlo7yisX3

[Clinical Infectious Diseases @CIDJournal]

Concerns regarding the probabilistic sensitivity analysis in the cost-effectiveness of universal hepatitis delta virus testing

✅ Just Accepted
🔗 https://t.co/cYgIjG4XHA

[Clinical Infectious Diseases @CIDJournal]

Field performance and acceptability of the hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) for detecting high viral load among pregnant women in The Gambia (PROTECT-B)

✅ Just Accepted
🔗 https://t.co/GdtWCNYwGG

[Clinical Infectious Diseases @CIDJournal]

How Much Is Enough? Refining Pragmatic Trial Design for Antimicrobial Stewardship

✅ Just Accepted
🔗 https://t.co/jyCifdNofq